Vical Inc. develops biopharmaceutical products based on DNA gene transfer technologies for the prevention and treatment of life-threatening diseases.
Total number of shares outstanding as of June 23, 2000 19,800,000
Price of each share of common stock on June 23, 2000 $19.625
Aggregate market value as of June 23, 2000 $388,575,000.00
For year ended Dec. 31, in thousands, except per-share data
1999 1998 1997
Contract Revenues $10,711 $5,920 $7,803
Net income (loss) $(6,909) $(7,481) $(5.611)
Net income (loss) per share $(0.43) $(0.47) $(0.36)
Total assets $45,059 $44,844 $50,691
R. Gordon Douglas Jr. has been chairman and director since May 1999. He was formerly president of Merck Vaccines.
M. Blake Ingle has been director since June 1996. He is a partner of Inglewood Ventures. He is also a director of Corvas International, Inc., Inex Pharmaceuticals and Burnham Institute.
Patrick F. Latterell has been director since February 1992. Since 1989, he has been general partner with Venrock Associates. He is also a director of Oratec Interventions Inc. and Signal Pharmaceuticals Inc.
Gary A. Lyons has been director since March 1997. Since 1993, he has been president, CEO and director of Neurocrine Biosciences, Inc. and has been a director of IntraBiotics Pharmaceuticals since December 1999.
Alain B. Schreiber has been president, CEO and director since May 1992. He is also a director of Spiros Development Corp. II.
Dale A. Smith has been director since August 1995. He was formerly group vice president of Baxter International Inc. He is also a director of Cerus Corp.
Philip M. Young has been director since February 1992. Since April 1990, he has been general partner of U.S. Venture Partners. He is also a director of The Immune Response Corp. and Zoran Corp.
Officers Cash Compensation
Alain Schreiber, president and CEO $420,000
Deirdre Y. Gillespie, executive vice president and chief business officer $274,000
Martha Demski, vice president and CFO $218,000
Jon Norman, vice president of research $217,000
George Gray, vice president of operations $206,000
Significant Stock Ownership
Number of shares Percent
March 1, 2000
State of Wisconsin Investment Board 1,252,000 6.33
Directors and executive officers as a group 1,346,574 6.38
Headquarters: 8373 Towne Centre Drive, Suite 100, San Diego, CA 92121; (858) 646-1100; fax (858) 646-1157; (www.vical.com)
Auditors: Arthur Andersen LLP, San Diego
Information was compiled from the company’s annual and proxy reports.